Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464–470.
Von Haehling S, Genth–Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002 Sep;85(1):173–183.
Cicoira M et al. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9(3):219–226.
Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J. 2003;4(4):232–235.
Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuos nasoenteric feeding. Am J Clin Nutr. 1989;50:539–544.
Paccagnella A, Cali MA, Caenaro G et al. Cardiac cachexia: preoperative and postoperative nutrition management. J Parenter Enteral Nutr. 1994;18(5):409–416.
Шестопалов А.Е., Матраева Ю.С., Дьяков А.Ю. и др. Нутритивная поддержка и коррекция метаболических нарушений у больных с ишемической болезнью сердца и дефицитом тощей массы тела при хирургической реваскуляризации миокарда. Сердечная Недостаточность. 2001;2;3.
Арутюнов Г.П., Костюкевич О.И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. Журнал Сердечная Недостаточность. 2002;3(5):245–248.
Руководство по парентеральному и энтеральному питанию под редакцией Хорошилова И.Е., Санкт–Петербург, 2001г, стр.179–181.
Арутюнов Г.П., Костюкевич О.И., Рылова Н.В. Применение сбалансированной смеси Пептамен для энтерального питания в лечении больных с ХСН. Журнал Сердечная Недостаточность. 2002;3(5):221–225.
Freeman LM, Roubenoff R. The nutrition implication of cardiac cachexia. Nutr Rev. 1994;52(10):340–347.
Paccagnella A, Cali MA, Caenaro G et al. Cardiac cachexia: preoperative and postoperative nutrition management. J Parent Enter Nutr. 1994;18(5):409–416.
Smith J, Redd S, Enteral formulation designed for cardiac cachexia. J Parent Enter Nutr. 1980;4:595A.
Yagi M, Taenaka N. Nutritional support in cardiac cachexia. Nippon Rinsho. 2001;59 Suppl:434–437.
Арутюнов Г.П., Костюкевич О.И., Влияние энтерального питания на толерантность к физическим нагрузкам и клиническую картину у больных с ХСН III–IV функционального класса. Кардиология. 2003;5.
Арутюнов Г.П., Костюкевич О.И., Рылова Н.В. Питание больных с ХСН: проблемы нутритивной поддержки (решенные и нерешенные аспекты) Терапевтический архив. 2003;8:88–92.
Fukui K, Suzuki S. Nutritional support in cardiac cachexia. Nippon Rinsho. 2001;59 Suppl:438–41.
Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the patogenesus and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3(6):417–424.
Осипова И.В., Ефремушкин Г.Г., Березенко Е.А. Длительные физические тренировки в комплексном лечении пожилых больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2002;3(5):218–221.
Арутюнов Г.П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Сердечная недостаточность. 2001;2(1):35–36.
Осипова И.В. "Свободный выбор нагрузки" физических тренировок – эффективный метод лечения хронической сердечной недостаточности. Сердечная недостаточность. 2001;2(4):176–180.
Exercise Standards. A statement for health professionals from the American Heart Association. Special Report. Circulation. 1990;82(6):2291.2292.
Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA Guidelines for exercise testing: Executive summary. Circulation. 1997;96:345.354.
Аронов Д.М. Кардиологическая реабилитация на рубеже веков. Сердце. 2002;1(3):123–125.
Осипова И.В. Длительные физические тренировки в комплексном лечении пожилых больных с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2002;3(5):218–220.
Sullivan MJ, Higginbotham MB, Cobb F.R. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation. 1988;78:506.515.
Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208.255.
Spencer FA, Meyer TE, Goldberg RJ. Twenty years trends (1975.1995) in the incidence, in.hospital and long.term death rates associated with heart failure complicating acute myocardial infarction. J Am Coll Cardiol. 1999;34;1378.1387.
Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36(7):2284.2286.
Jong P, Vowinckel E, Liu PP et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population.based study. Arch Intern Med. 2002;162:1689.94.
Stromberg A. The crucial role of patient education in heart failure. Eur J Heart Fail. 2005;7:363.369.
Агеев Ф.Т., Мареев В.Ю., Середенина Е.М., Беленков Ю.Н. Перспективы внедрения специализированных форм активного амбулаторного ведения больных с сердечной недостаточностью: структура, методика и предварительные результаты Российской программы "ШАНС". Сердечная недостаточность. 2004;5(6):268–271.
Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left. ventricular systolic function intolerant to angiotensin.converting.enzyme inhibitors: the CHARM.Alternative trial. Lancet. 2003;362:772.6.
McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin.convertingenzyme inhibitors: the CHARM.Added trial. Lancet. 2003;362:767.71.
Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left. ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362:777.81.
Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547.52.
Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049.57.
Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709.17.
Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V.HeFT III Circulation. 1997;96:856.863
Thackray S, Witte K, Clark AL, Cleland JG ..Clinical trials update: OPTIME.CHF, PRAISE.2, ALL.HAT. Eur J Heart Fail. 2000;2(2):209.12
Фомин И.В. Как мы лечим АГ и ХСН в реальной практике: уроки Российского исследования ЭПОХА Журнал Сердечная недостаточность. 2004;5(2):53–54
The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Failure. 1999;20:139.144.
Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme..a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464.74
EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997;18(10):1569.82
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries;principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22(7):554.72
Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin. converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995;273(18):1450.1456.
Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. – Медикаментозные пути улучшения прогноза больных с хронической сердечной недочстаточностью. Москва, Инсайт, 1997, 77с
NSAIDS and heart failure. Review. Prescire Int. 2001;10:182.183
Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local forearm vasodilation with intra.arterial administration of enalaprilat in humans. Clin Pharmacol Ther. 1991;50:314.21.
Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и соавт., – Применение диклофенака и целебрекса у пациентов с артериальной гипертонией и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Журнал Сердечная недостаточность. 2005;6(33):204–208
Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20:1549.55.
Мареев В.Ю. Взаимодействие лекарственных средств при лечении больных с сердечно–сосудистыми заболеваниями. 1. Ингибиторы АПФ и аспирин. Есть ли повод для тревоги? Сердце. 2002;1(4):161–168
Al Khadra AS, Salem DN, Rand WM et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419.25.
Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115.119.
Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin.converting enzyme inhibitors. Am J Cardiol. 2003;91:1350.2.
Spaulding C, Charbonnier B, Cohen.Solal A et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double.blind, randomized comparative trial. Circulation. 1998;98:757.65.
Лопатин Ю.М. Совместное применение аспирина и ингибиторов АПФ при ХСН: позиция "За". Журнал Сердечная недостаточность. 2003;4(19):149–152
Мареев В.Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная недостаточность. 2003;4(19):153–157
Teo KK, Yusuf S, Pfeffer M et al. Effects of long.term treatment with angiotensin.converting.enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002;360:1037.1043.
Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin.converting enzyme inhibitors does not worsen long.term survival in heart failure. Int J Cardiol. 2003;88:207.14.
Antithrombotic TrialistsЎЇ Collaboration . Collaborative meta.analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients¬р BMJ. 2002;324:71.86
Shekelle PG, Rich MW, Morton SC. Efficacy of angiotensin.converting enzyme inhibitors and beta.blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta.analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529.1538.
The SOLVD investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl. J Med. 1992;327:685.691
The SOLVD investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. J Med. 1991;325:293.302
Cohn Jn, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine.isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303.310
McKelvie RS, Rouleau J.L, White M et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003;24:1727.1734
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429.35.
Dickstein K, Kjekshus J and OPTIMAAL steering committee. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute muocardial infarction: the OPTIMAAL randomized trial. Lancet. 2002;360:752.760
Kleber FX, Doering W. Prognosis of mild chronic heart failure: effects of the ACE inhibitor captopril. Herz. 1991;16 Spec No 1:283.293
Kleber FX, Niemoller L. . Long.term survival in the Munich Mild Heart Failure Trial (MHFT). Am J Cardiol. 1993;71(13):1237.1239
Captopril Multicenter Research Group. A placebo.controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755.63.
Pitt B, Poole.Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582.7.
Borghi C, Marino P, Zardini P et al..Short. and long.term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J. 1998;136(2):213.225
Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M, for the Fosinopril Efficacy/Safety Trial (FEST) Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 1995;16:1892.1899.
Brown EG, Cheu PH, MacLean A et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 1995;75:596.600
Zannad F, Chati Z, Guest M et al. Differential effect of fosinopril end enalapril in patients with mild to moderate CHF. Am Heart J. 1998;136:672.680
Cleland JG, Tendera M, Adamus J et al. PEP.CHF Investigators The perindopril in elderly people with chronic heart failure (PEP.CHF) study Eur Heart J. 2006;27(19):2338.45.
Massie BM, Armstrong PW, Cleland JG et al. Toleration of high doses of angiotensin.converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial: the Assessment of Treatment with Lisinopril and Survival. Arch Intern Med. 2001;161:165.71.
Giles TD, Katz R, Sullivan JM, et al, for the Multicenter Lisinopril.Captopril Congestive Heart Failure Study Group. Short. and long.acting angiotensin.converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol. 1989;13:1240.7.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821.8.
Riegger GA. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J. 1991;12(6):705.11
Pflugfelder PW, Baird MG, Tonkon MJ et al. for the Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin.converting enzyme inhibitor withdrawal in chronic heart failure: a double.blind, placebo.controlled study of quinapril. J Am Coll Cardiol. 1993;22:1557.63.
Beynon JH, Pathy MS. . An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heartfailure. Curr Med Res Opin. 1997;13(10):583.92
Скворцов А.А., Насонова С.Н., Сычев А.В. И соавт. – Комбинированное применение ингибитора ангиотензинпревращающего фермента квинаприла и блокатора рецепторов 1–го типа к ангиотензину II валсартана у больных с умеренной хронической сердечной недостаточностью: возможно ли повышение степени нейрогормональной блокады и улучшение параметров суточной вариабельности ритма сердца по сравнению с действием монотерапии (по результатам исследования САДКО–ХСН) Тер архив, 2005;77:34–43
Widimsky J, Kremer HJ, Jerie P et al. . Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active.controlled, double.blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995;49:95.102
Мареев В.Ю., Ольбинская Л.И., Мартынов А.И. – Проспективное, многоцентровое, открытое исследование эффективности и переносимости КВАдроприла у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилатационной кардиомиопатией (Исследование КВАНК) Журнал Сердечная Недостаточность. 2006;7 (в печати)
Sica DA, Cutler RE, Parmer RJ et al. Comparison of the steady.state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 1991;20(5):420.427
Greenbaum R, Zucchelli P, Caspi A et al.,Comparison of the pharmacokinetics of fosinopril with enalaprilat and lisinopril in patients with CHF and chronic renal insufficiency. Br.J.Clin.Pharmacol., 2000:49, 23.31
Ferrari R, Effects of angiotensin.converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166(6):659.66
Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin.converting.enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058.68
Мареев В.Ю. Ингибиторы ангиотензин превращающего фермента в лечении больных с коронарной болезнью сердца. Взгляд 2003 года. "Кардиология". 2003;42(12):3–10
Packer M, Lee WH, Medina N et al. Functional renal insufficiency during long.term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987;106:346.54.
Packer M, Lee WH, Kessler PD et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol. 1987;10:837.44.
David D, Jallad N, Germino W et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with history of ACE inhibitor . associated cough. Am. J Theraputic. 1995;2 :806.813
Mac Fadyen RJ, Lees KR, Reid JL . Differences in first.dose response of angiotenzine converting enzyme inhibition in congestive heart failure. Br Heart J. 1991;66:206.211.
Navookarasu NT, Rahman A, Abdullah I et al. First.dose responce to angiotensin converting enzyme inhibition in chronic cardiac failure: a Malaysian experience. Int J Clin Pract. 1999 ;53(1):25.30
The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 1998;19:481.489.
Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995;49(5):750.66
Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819.23
Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724.1729
Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. – Хроническая сердечная недостаточность. Избранные лекции по кардио-логии. – М.: ГЭОТАР–Медиа, 2006 – 432 стр.
Мухарлямов Н.М, Наумов В.Г., Орлова А.И – Сочетаное применение бета – адреноблокаторов в комбинации с сердечными гликозидами для лечения больных с дилатационными кардиомиопатиями и сердечной недостаточностью. Бюлл. ВКНЦ, 1978;1:78–82
Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta.adrenergic pathway. Circulation. 1998;98:1329.1334.
Беленков Ю.Н., Мареев В.Ю., Скворцов А.А. и др. Клинико–гемодинамические и нейрогуморальные эффекты длительной терапии бета–адреноблокатором бисопрололом больных с тяжелой хронической сердечной недостаточностью. Кардиология. 2003;10:11–22.
Metra M, Nardi M, Giubbini R, Dei CL. Effects of short. and long.term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678.87.
Olsen SL, Gilbert EM, Renlund DG et al.. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double.blind randomizedstudy. J Am Coll Cardiol. 1995;25:1225.31.
Беленков Ю.Н., Мареев В.Ю., Скворцов А.А. и соавт. Эналаприл против Карведилола. Сравнительное рандо- мизирован–ное исследование у больных с хронической сердечной недостаточностью (ЭКСТАЗ) Сердечная Недостаточность. 2001;2(2):84–91
Packer M, Bristow MR, Cohn JN et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349.55.
Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo.controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375.80.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS.II): a randomized trial. Lancet. 1999;353:9.13.
MERIT.HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT.HF). . Lancet. 1999;353:2001.2007
Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651.1658.
Mareev V, Yu.Lopatin Yu, Pervez Gh. Possible mechanisms of positive beta.blocker effects in the treatment of dilated cardiomyopathy. Eur Heart J. 1993;14:94
Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 2000;34:320.4.
Cleland JG, Pennell DJ, Ray SG et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14.21.
Waagstein F, Bristow MR, Swedberg K, et al, for the Metoprololin Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficialeffects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441.6.
Poole.Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7.13.
Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure(SENIORS). Eur Heart J. 2005;26(3):215.25
Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation. 2005;112(16):2426.2435
Erdmann E, Lechat P, Verkenne P, Wiemann H.Results from post.hoc analyses of the CIBIS II trial: effect of bisoprolol in high.risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3(4):469.79
Deedwania PC, Gottlieb S, Ghali JK et al. Efficacy, safety and tolerability of beta.adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J. 2004;25(15):1300.9
Middeljans.Tijssen CW, Jansen RW. Elderly heart failure patients and the role of beta.blockertherapy. Tijdschr Gerontol Geriatr. 2006;37(2):67.77
Ghali JK; Pina IL;. Gottlieb SS et al. Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended.Release Randomized Intervention Trial in Heart Failure (MERIT.HF). Circulation. 2002;105:1585. 1591
Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long.term beta.blockade in dilated cardiomyopathy: effects of short. and long.term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551.563.
Gattis WA, OЎЇConnor CM, Leimberger JD et al. ,.. Clinical outcomes in patients on beta.blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91:169.74.
Dorow P, Thalhofer S, Bethge H et al. ,Long.term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double.blind crossover study. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S36.44
Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta.blockers on albuminuria in patients with type 2 diabetes., Hypertension. 2005;46(6):1309.15
Follath F, Cleland JGF, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low.output heart failure (The LIDO study): A randomizes double.blind trial. Lancet. 2002, 360:196.202
Виноградов А.В. Мочегонные средства в клинике внутренних болезней. М. – Медицина, 1969. 151 с.
Мухарлямов Н.М., Мареев В.Ю. Лечение хронической сердечной недостаточности. М. – Медицина, 1985, 207 с
Kjekshus J, Swedberg K. . Tolerability of enalapril in congestive heart failure. Am J Cardiol. 1988;62(2):67A.72A
Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.CONSENSUS Trial Study Group. Circulation. 1990;82(5):1730.6
Ljungman S, Kjekshus J, Swedberg K. . Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial).Am J Cardiol. 1992;70(4):479.87
Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10:297.303.
Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543.51.
McMurray JJV, OЎЇMeara E. Treatment of Heart Failure with Spironolactone . Trial and Tribulations. N Engl J Med. 2004;351:526.528
Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med. 1994;154:1905.14.
Patterson JH, Adams KF Jr, Applefeld MM et al. for the Torsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14:514.21.
Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387.95.
Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose.response curves. Clin Pharmacol Ther. 1980;28:182.6.
Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314.8.
Dormans TP, van Meyel JJ, Gerlag PG et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376.82.
Vargo DL, Kramer WG, Black PK et al.. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601.9.
Brater D. Torasemid: pharmacokinetic and clinical efficacy Eur J Heart Fail. 2001;3(Suppl G):19.24
Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II.induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34(1):138.43
Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67(5):384.390
Muller K, Gamba G, Jaquet F, Hess B. . Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV..efficacy and quality of life. Eur J Heart Fail. 2003;5(6):793.801
Stroupe KT, Forthofer MM, Brater DC, Murray MD.Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17(5):429.440.
Cosin J, Diez J,Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507.13
Jones PW, Greenstone M. . Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001;(1):CD002881
Philippi H, Bieber I, Reitter B. . Acetazolamide treatment for infantile central sleep apnea. Drugs.2001;61(2):237.51.
Javaheri S ..Acetazolamide improves central sleep apnea in heart failure: a double.blind, prospective study. Am J Respir Crit Care Med. 2006;173(2):234.7
Cleland JG, Coletta AP, Nikitin NP et al. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail. 2006;8(3):326.9
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336(8):525.33
Uretsky BF, Young JB, Shahidi FE et al. for the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993;22:955.62.
Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin.converting.enzyme inhibitors: RADIANCE Study. N Engl J Med. 1993;329:1.7.
Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959.64.
Akera T, Baskin SI, Tobin T, Brody TM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K + ).activated ATPase. Naunyn Schmiedebergs Arch Pharmacol. 1973;277:151.62.
Ferguson DW, Berg WJ, Sanders JS et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation. 1989;80:65.77.
Gheorghiade M, Ferguson D. Digoxin: a neurohormonal modulator in heart failure? Circulation. 1991;84:2181.2186.
Нарусов О.Ю., Мареев В.Ю., Скворцов А.А. и др. – Клинические, гемодинамические и нейрогормональные эффекты дигоксина у больных с ХСН Серд. Недостаточность, 2000, т.1,№1, с. 26–30
Rathore SS, Curtis JP, Wang Y et al. ,Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871.8
Adams KF, Patterson JH, Gattis WA et al. , Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497.504
Cohn JN, Tognoni G. A randomized trial of the angiotensin.receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667.75.
Maggioni A¬І, Anand I, Gottlieb SO et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin.Converting Enzyme Inhibitors JACC. 2002;40,:1414.21
Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val.HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970.5.
Скворцов A.A., Насонова С.Н., Сычев AВ и др. Эффекты длительной терапии ингибитором ангиотензинпревращающекго фермента квинаприлом, антагонистом рецепторов к ангиотензину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточности. Основные результаты исследования САДКО–ХСН. Кардиология 2006;46:33–51
Скворцов A.A., Мареев В.Ю., Насонова С.Н. и др Рекомендована ли тройная комбинация нейрогормолнальных модуляторов для лечения умеренной и т тяжелой ХСН? (результаты исследования САДКО–ХСН). Терю архив, 2006;78(8):14–20
Haehling S, Okonko DO, Anker SD. Statins: a treatment option for chronic heart failure? . Heart Fail Monit,2004;4:90.97
Sacks FM, Pfeffer MA, Moye LAet al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med, 1996;335:1001 . 1009
D.P.Mikhailidis AS.Werzbicki. The Greak atorvastatin and coronary heart disease evaluation (GREACE) study . CurrMed Res and Opin. 2002;18(4):220.228
D.Nul, A.Fernandez, C.Zambrano et al. Statins and mortality in congestive heart failure: benefit beyond cholesterol reduction? . JACC. 2005;45(suppl A):851.4
Jaganmohan S, Khurana V. Statins improve survival in patients with congestive heart failure: a study on 32000 US veterans. JACC. 2005;45(suppl A):854.7
Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. The Eur J Heart Fail. 2005;7:1059.1069
Tavazzi L, Tognoni G, Franzosi MF et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n.3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635.641.
Horwich TB, MacLellan R, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non.ischemic heart failure. J Am Coll Cardiol. 2004;43:642.648.
Ray GR, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62.67.
J LiaoK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med. 2004;52:248.253
Gao L, Wang W, Li YL et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation. 2005;112(12):1763.1770
R. U. Pliquett, K. G. Cornish, J. D. Peuler et al. Simvastatin Normalizes Autonomic Neural Control in Experimental Heart Failure. Circulation. 2003;107:2493.2498
S. Von Haehling, S.D.Anker, E.Bassrnge . Statins and role of nitric oxide in chronic heart failure. Heart Fail Rev. 2003;8:99.106
Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short.term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839.843.
Thomas H, Muhlestein JB, Carlquist JF et el.A cholesterol paradox in congestive heart failure survival? JACC. 2005;45(su¬вpl A):851.5
Horwich B, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216.224.
Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933.1944.
Dunkman WB, Johnson GR, Carson PE et al. for the V.HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993;87:VI94.101.
Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk. 1995;2:107. 17.
Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? J Cardiovasc Risk. 1995;2:97.102.
Cioffi G, Pozzoli M, Forni G et al. Systemic thromboembolism in chronic heart failure: a prospective study in 406 patients. Eur Heart J. 1996;17:1381.9
Fuster V, Gersh BJ, Giuliani ER et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525.31.
Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of eft ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78:1388.93.
Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793.800
Turpie AG.Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86(12B):48M.52M
Leizorovicz A, Cohen AT, Turpie AG. G et al. randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely Ill medical patients: the PREVENT medical thromboprophylaxis study Supplement to the Journal of Thrombosis and Haemostasis July. 2003(ISSN 1740 3340). Abstract OC396
Ageno W, Turpie AG. Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clin Cornerstone. 2005;7(4):16.22
Al Khadra AS, Salem DN, Rand WM et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749.53.
Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903.12
Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE.HF extension study, ESSENTIAL, CIBIS.III, S.ICD, ISSUE.2, STRIDE.2, SOFA, IMAGINE, PREAMI, SIRIUS.II and ACTIVE. Eur J Heart Fail. 2005;7(6):1070.5
Baker DW, Wright RF. Management of heart failure, IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA. 1994;272:1614.1618.
Dries DL, Domanski MJ, Waclawiw MA et al. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol. 1997;79:909.13
Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator.Heart Failure Trial Study Group. . Racial differences in response to therapy for heart failure: analysis of the vasodilator.heart failure trials. J Card Fail. 1999;5:178.87.
Шарашидзе М.Л., Мареев В.Ю., Суворов Ю.И. и др. Влияние изосорбида динитрата на водные пространства орга- низма при хронической недостаточности кровообращения. Тер. архив. 1989;61(6):119–122
Packer M, OЎЇConnor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107.14
Connor CM, Carson PE, Miller AB et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82(7):881.7
W.B.Kanel, J.F.Plehn, L.A.Cupples. Cardiac failure and sudden death in the Framingham Study. Am. Heart J.,1988;v.115: p.869.875
Luu M, Stevenson WG, Stevenson LW et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675.80.
Мареев В.Ю. Сердечная недостаточность и желудочковые нарушения ритма сердца: проблема лечения. Кардиология. 1996;36,(12):.4–12
Hjalmarson A, Goldstein S, Fagerberg B, et al, for the MERIT.HF Study Group. Effects of controlled.release metoprolol on total mortality, hospitalizations, and well.being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT.HF). JAMA. 2000;283:1295.302.
Poole.Wilson PA, Uretsky BF, Thygesen K et al. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;Vol. 89:p. 42.48
Казей Д.В., Мареев В.Ю., Мухарлямов Н.М. Влияние изменений гемодинамики на нарушения ритма сердца: опыт длительного внутривенного введения раствора нитроглицерина больным с сердечной недостаточностью. Бюлл. Всесоюзн.кардиол. научн. центра, 1989;2:20–25
Казей Д.В., Мареев В.Ю., Агеев Ф.Т. и др. Влияние периферических вазодилататоров на нарушения ритма сердца у больных с хрони–ческой сердечной недостаточ–ностью. Кардиология.1992;32,(4):30–34
Myerburg RJ, Mitrani R, Interian A et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97:1514.1521.
CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction in sudden death after one year. Cardiovasc J S Afr. 2006;17(5):278
Amiodarone Trials Meta.Analysis Investigators. Effect of prophylactic amiodarone on mortality after acure myocardial infarction and in congestive heart failure: meta . analysis of individual data from 6500 patients in randomized trials. Lancet. 1997;359:1417.1424.
Мареев В.Ю. Возможно ли успешное предотвращение внезапной смерти у больных с хронической сердечной недо- статочностью и дисфункцией левого желудочка. Препараты или аппараты? "Кардиология". 2004;42(12):4–15.
Boutitie J.P/ Boissel, SJ. Connolly et al. Amiodarone Interaction With Ґв.Blockers. Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation. 1999;99:2268.2275
Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter.defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225.237
Singh SN, Poole J, Anderson J et al. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J. 2006;152(5):974.e7.11
Kovoor P, Eipper V, Byth K et al. Comparison of sotalol with amiodarone for long.term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J. 1999;20:364.374
Беленков Ю.Н., Сангонова Д.Ф., Агеев Ф.Т., Мареев В.Ю. Сравнительное исследование длительного применения соталола, метопролола и амиодарона у больных с тяжелой сердечной недостаточностью и прогностически опасными желудочковыми нарушениями ритма сердца. Кардиология,1996;36:37–48.
MacNeil JH. Review of Sotalol safety in 3257 patients with arrhythmias after 15 June. 1991. Bristol Myers Squibb report, 1993. Data on file.
Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med. 1999;341:910–1.
Dries DL, Exner DV, Gersh BJ, et al, – Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695–703.
Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 1997;78:564–8.
Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22:1852–923
Wyse DG, Waldo AL, DiMarco JP et al. The Atrial Fibrillation Follow–up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:825–33
Van Gelder IC, Hagens VE, Bosker HA et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl J Med. 2002;347:1834–40.
Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial fibrillation? QJM. 2003;96:881–92
Hylek EM, Skates SJ, Sheehan MA and Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation in for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–546
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic treatment to prevent stroke in patients with atrial fibrillation: a meta–analysis. Ann Intern Med. 1999;131:492–501
Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic Drug Substudy Investigators. J Am Coll Cardiol. 2003;42:20–29
Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm. Arch Intern Med. 2003;163:777–785
Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. – Adverse effects of amiodarone: pathogenesis, incidence and management. Med Toxicol Adverse Drug Exp. 1989;4:246–253.
Greene HL, Graham EL, Werner JA et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol. 1983;2:1114–1128.
Roy D, Talajic M, Dorian P, Connolly S et al.. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–920
Lundstrom T, Ryden L. Chronic atrial fibrillation. Long–term results of direct current cardioversion. Acta Med Scand. 1988;223:53–59
Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin–converting enzyme inhibitors and angiotensin receptor blockers: a meta–analysis. J Am Coll Cardiol. 2005;45(11):1832–1839
Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res. 1991;25:453–7.
David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378–82.
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open–label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–10.
Khand AU, Rankin AC, Martin W,et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42:1944–51.
Davie AP, Love MP, McMurray JJ. Even low – dose aspirin inhibits arachidonic acid – induced vasodilation in heart failure. Clin.Pharmacol.Ther. 2000;67:530–537
Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin – converting enzyme inhibitors. Am.Heart.J. 1999;138:254–260
Атауллаханова Д.М., Мареев В.Ю. Влияние лазикса на центральную гемодинамику у больных с сердечной недостаточностью. Тер. Арх. 1980;11:109–112
Jhunds PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:1234–1238
Lindfeld J.A, Robertson A.D, Lowes B.D et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta – blockers. J.Am.Coll.Cardiol. 2001;38:1950–1956
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events(CAPRIE). Lancet. 1996;348:1329–1339
Yusuf S, Zhao F, Mehta S.R et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST–segment elevation. N Engl J Med. 2001;345:494–502
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.
Cleland JGF. Aspirin: does it have a role in the treatment of heart failure due to ischemic heart disease? In book.: Coats A. (ed) Controversies in the management of heart failure. Churchill Livingstone. 1997:69–82
Hayden M, Pigone M, Phillips et al. Aspirin for primary prevention of cardiovascular events: a summary of the evidence for U.S. Preventive Services Task Force. Ann.Intern.Med. 2002;136:161–172
Peterson JG, Topol EJ, Sapp SK et al. Evaluation of the effect of aspirin combined with angiotensin – converting enzyme inhibitors in patients with coponary artery disease. Am J Med. 2000;109:371–377
Latini R, Tognioni G, Maggioni A.P et al. Clinical effects of early angiotensin – converting enzyme inhibitor treatment for acute myocardial infarction are similar in presence ana absence of aspitin: systematic overview of individual data from 96712 randomized patients. Angiotensin – converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J.Am. Coll.Cardiol. 2000;35:1801–1807
Flather MD, Yusuf S, Kober L et al. Long – term ACE – inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE – inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355:1575–1581
Takkouche, Etminan M, Caamano F. et al Interaction between aspirin and ACE inhibitors: resolving discrepancies using a meta– nalysis. Drug Saf. 2002;25:373–378
Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J. 1991;121:1956–64.
Hatzizacharias A, Makris T, Krespi P et al. Intermittent milrinone effect on long–term hemodynamic profile in patients with severe congestive heart failure. Am Heart J. 1999;138:241–6.
Uretsky BF, Jessup M, Konstam MA, et al, for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation. 1990;82:774–80.
Feldman AM, Bristow MR, Parmley WW, et al, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329:149–55.
Packer M, Carver JR, Rodeheffer RJ, et al, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–75.
Applefeld MM, Newman KA, Sutton FJ et al. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J. 1987;114:589–95.
Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double–blind, placebo–controlled study. Clin Pharmacol Ther. 1998;63:682–5.
Caffe M.S, Califf R.M,Adams K.F et al. Short–term inthavenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. JAMA. 2002;287:1541–1547.
Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J.2005,26,1115–1140
Moiseev VS, Poder P, Andrejevs N. et al. Safety and efficacy of a novel calcium sansitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J. 2002;23:1422–1432
Диагностика и лечение фибрилляции предсердий. Российские рекомендации. Разработаны Комитетом экспертов ВНОК. Москва. 2005.
Philbin EF, Rocco TA. Use of angiotensin–converting enzyme inhibitors in heart failure with preserved ventricular systolic function. Am Heart J. 1997;134:188–95
Карпов Ю.А., Мареев В.Ю., Чазова И.Е.. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ,ФАСОН,ФАГОТ). Журнал Сердечная Недостаточность. 2003;5:261–265.
Cleland JGF. The perindopril in elderly people with chronic heart failure (PEP–CHF) study. Hot Line I Session on XVth World Congress of Cardiology, Barcelona, 03 September 2006.
Klingbeil AU et al. A meta–analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46.
Мареев В.Ю., Овчинников А.Г., Агеев Ф.Т., Беленков Ю.Н.. Влияние ингибиторов АПФ и антагонистов рецепторов к ангиотензину–II на диастолическую функцию левого желудочка у пациентов с относительно сохранной систоли- ческой функцией левого желудочка: результаты исследования "Периндоприл,ИРбесартан и АмлодипиН у болЬных с ХСН и сохраненной систолической функцией левого желудочка (ПИРАНЬя). Журнал Сердечная Недостаточность. 2005;1:4–14.
Bergstrom A, Anersson B, Ender M et al Effect of carvedilol on diastolic function in patients with diastolic heart failure and reserved systolic function. Results of Swedish Doppler–echocardiographic study. Eur J Heart Failure. 2004;6:453–462
The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol. 1990;66:331–401
Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028–2035
Ali Ahmed, Rich MW, Love TE et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–186
Рекомендации Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции по проведению клинических электрофизиологических исследований, катетерной абляции и имплантации антиаритмических устройств. – Москва. 2005, 238 с.
Zipes D, Camm J et al. ACC/AHA/ESC 2006 guidelins for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary. JACC. 2006;48:1064–1108.
Bristow M, Saxon L, Boehmer J et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac–resynchrozation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
Cleland J, Daubert J, Erdmann E et al. Cardiac Resynchronization – Heart Failure (CARE–HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352:1539–1549.
Abraham W, Young J, Leon A et al. Multicenter InSync ICD II Study Group. Effects of cardiac resynhronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter– defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–2868.
Lee D, Green L, Liu P et al. Effectivenes of implantable defibrillators for preventing arrhythmic events and death: a meta–analysis. JACC. 2003;41:1573–1582.
The Antiarrhytmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic–drug therapy with implantable defibrillators in patients resuscited from near–fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583.
Kadish A, Dyer A, Daubert J et al. Prophylactic defibrillator implantation in patients with nonishemic dilated cardiomyopathy. N Engl J Med. 2004; 350: 2151–2158.
Moss A, Hall W,Cannom D et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–1940.
Buxton A, Lee K, Fisher J et al. A randomized study of prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882–1890.
Moss A, Zareba W, Hall W et al. Prophylactic implantation of a defiblirillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
Rose EA, Gelijns AC, Moskowitz AJ. Long–term mechanical left ventricular assistance for end–stage heart failure. N Engl J Med. 2001;345(20):1435–1443.
Источник: www.cardiosite.ru
|
